Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures

Rhea-AI Summary

Medtronic (NYSE: MDT) received FDA clearance for the Stealth AXiS™ surgical system for cranial and ENT procedures on March 27, 2026. The system unifies planning, navigation, robotics and AI-enabled tractography inside the AiBLE™ ecosystem, and was cleared for spine in February.

The platform integrates intraoperative ultrasound via GE HealthCare bkActiv™ and is designed for continuous software innovation and multi-specialty connectivity.

Positive

• FDA clearance for cranial and ENT procedures (March 27, 2026)
• Previously cleared for spine procedures in February 2026
• AI-based automatic tractography for patient-specific brain mapping
• Integration with GE HealthCare bkActiv intraoperative ultrasound
• Platform supports multi-specialty use and continuous software updates

Negative

• None.

News Market Reaction – MDT

-0.60%

-0.60% Session close to close

In the Mar 27 session, MDT declined 0.60%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands the FDA-cleared use of the Stealth AXiS™ system from spine into cranial an...

Analysis

This announcement expands the FDA-cleared use of the Stealth AXiS™ system from spine into cranial and ENT procedures, unifying planning, navigation, and robotics on one platform. It builds on prior architecture designed for multi-specialty use, adding AI-based tractography and integrated intraoperative imaging. In context of Medtronic’s broader stream of device clearances and its existing robotics footprint, investors may focus on adoption trends, procedure volumes, and future indication expansions as key metrics to watch.

Key Figures

Navigation leadership: 25 years

1 metrics

Navigation leadership 25 years Duration of Medtronic’s navigation leadership referenced for ENT surgery

Previous Clinical trial,fda approval Reports

5 past events · Latest: Feb 13 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 13	Spine system clearance	Positive	-1.4%	FDA clearance of Stealth AXiS™ platform for spine surgery navigation and robotics.
Jan 12	Diabetes device clearance	Positive	-0.6%	FDA 510(k) clearance of MiniMed Go™ Smart MDI system linking pen and CGM.
Dec 03	Hugo RAS clearance	Positive	+0.0%	FDA clearance of Hugo™ RAS system for urologic procedures after positive trial data.
Apr 25	Defibrillation lead approval	Positive	-0.1%	FDA approval for OmniaSecure™ smallest-diameter lumenless defibrillation lead.
Nov 20	InPen app clearance	Positive	-1.1%	FDA clearance of new InPen™ app enabling Smart MDI system with Simplera™ CGM.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

For FDA/clinical milestones, MDT has often seen flat-to-negative next-day moves, with an average same-tag reaction of -0.63% and 4 of 5 past events trading down despite positive regulatory news.

Recent Company History

Over the past year, Medtronic has repeatedly announced FDA clearances and approvals across robotics, diabetes, urology, and cardiac devices. Prior events include spine clearance for the Stealth AXiS™ platform, multiple diabetes-related 510(k) clearances, and approvals for the OmniaSecure™ defibrillation lead and Hugo™ RAS system. These milestones show a steady cadence of regulatory progress, but immediate share reactions have generally been modest or slightly negative, suggesting investors may already price in a robust innovation pipeline.

Key Terms

tractography, intraoperative ultrasound, ent, ai-enabled, +4 more

8 terms

tractography medical

"the system includes AI-based automatic tractography that helps surgeons generate patient-specific brain maps"

Tractography is an imaging method that uses MRI data to map the brain’s internal wiring by tracking the paths of water movement along nerve fiber bundles. For investors, it matters because it underpins advanced diagnostics, surgical planning, and the development of medical devices or software that analyze brain connectivity — similar to a GPS map for a city’s highways, helping doctors and companies locate and navigate critical routes.

intraoperative ultrasound medical

"The platform also integrates intraoperative ultrasound through GE HealthCare's bkActiv™"

Intraoperative ultrasound is the use of real‑time sound‑wave imaging by surgeons during an operation to see internal organs, tumors, blood vessels and surgical tools as they work. Think of it as a live map or GPS inside the body that helps surgeons find targets, avoid damage, and make quicker decisions. Investors care because wider use can improve outcomes, shorten surgeries, raise demand for compatible devices and software, and influence hospital purchasing and reimbursement trends.

ent medical

"for cranial and ear, nose, and throat (ENT) procedures"

ENT stands for ear, nose and throat medicine, the medical field that diagnoses and treats conditions of the head and neck such as sinus disease, hearing loss, voice disorders and throat infections. For investors, ENT matters because new drugs, devices or approvals in this area can create or change markets—think of it as a product line for healthcare companies focused on everyday problems like hearing and breathing that affect large numbers of people.

ai-enabled technical

"bringing together advanced navigation, robotics, and AI-enabled capabilities within the AiBLE™ smart ecosystem"

AI-enabled describes a product, service, or process that uses artificial intelligence—software that learns from data and makes decisions or predictions—as a core feature rather than a minor add-on. For investors it matters because AI-enabled offerings can boost productivity, lower costs or unlock new revenue streams; like adding a smart autopilot to a routine task, they can change a company's growth potential and competitive edge while also bringing higher upfront investment needs and distinct regulatory or ethical risks.

neural pathway medical

"visualize critical neural pathway associated with essential brain functions"

A neural pathway is a chain of nerve cells that carry signals between parts of the brain or between the brain and the body, like electrical wiring that lets different rooms in a house talk to each other. For investors, neural pathways matter because drugs, devices or therapies that change how these circuits work can alter symptoms or disease progression, shaping clinical results, market size, regulatory review and the commercial value of medical products.

minimally invasive endoscopic surgery medical

"Intraoperative navigation is critical in minimally invasive endoscopic surgery of the sinuses and skull base"

Surgery performed through small cuts using a thin tube with a camera and instruments to view and treat internal organs rather than opening the body wide. Think of it as fixing something through a keyhole instead of taking the whole door off. Investors care because it typically shortens hospital stays, lowers complication and recovery costs, speeds patient turnover, and can boost demand for specialized devices, technologies, and outpatient services that affect healthcare revenues and margins.

intraoperative navigation medical

"Intraoperative navigation is critical in minimally invasive endoscopic surgery of the sinuses"

A surgical guidance system used during an operation to show a surgeon where instruments and implants are inside the body, much like a GPS shows a driver’s position on a map. Investors care because these systems can shorten procedures, reduce complications and support higher-value treatments, influencing a medical device maker’s sales, regulatory approvals, reimbursement prospects and competitive standing.

ecosystem technical

"AI-enabled capabilities within the AiBLE™ smart ecosystem to support surgeons"

An ecosystem is the network of companies, customers, suppliers, partners, technologies and services that interact around a product, platform or market — like a neighborhood of businesses and users that rely on one another. For investors it matters because a strong ecosystem can multiply revenue streams, make a product harder to displace, and spread risk across multiple participants, while a weak or shrinking ecosystem can limit growth and increase vulnerability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GALWAY, Ireland, March 27, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform.

"Cranial procedures require an exceptional level of precision, planning, and real-time insight," said Michael Carter, Senior Vice President and President of Medtronic Cranial & Spinal Technologies. "With the Stealth AXiS™ surgical system, we are bringing together advanced navigation, robotics, and AI-enabled capabilities within the AiBLE™ smart ecosystem to support surgeons with deeper insights across the surgical workflow."

A defining capability of the platform is its AI-enabled architecture, which supports advanced planning and visualization before, during, and after surgery. For cranial procedures, the system includes AI-based automatic tractography that helps surgeons generate patient-specific brain maps and visualize critical neural pathway associated with essential brain functions. The platform also integrates intraoperative ultrasound through GE HealthCare's bkActiv™, providing additional real-time imaging during procedures.

"For complex brain surgeries, the more information you have, the better decisions you can make," said Dr. Michael Ivan, neurosurgeon at the University of Miami Health System. "Pre-operative planning with tools like tractography may help surgeons enhance surgical efficiency and support better patient outcomes." ^1,2

For ENT procedures, the Stealth AXiS™ surgical system delivers high-precision navigation and advanced visualization tailored to the intricate anatomy of the sinuses and skull base. Built around real-world ENT workflows, the system offers sharper anatomical detail and faster responsiveness to support confident decision-making in the OR, as well as intuitive, surgeon-centered workflows to create a familiar user experience while delivering enhanced capabilities.

"Intraoperative navigation is critical in minimally invasive endoscopic surgery of the sinuses and skull base, helping surgeons confidently delineate complex anatomy within high-risk spaces," said Dr. Vijay Ramakrishnan, board-certified otolaryngologist and professor of Otolaryngology-Head & Neck Surgery at Indiana University School of Medicine. "The Stealth AXiS™ system leverages innovative technologies to enhance surgeon workflows and support procedural efficiency and confidence in the operating room."

Additionally, the system's flexible architecture is designed to support continuous software innovation, expanded capabilities, and deeper ecosystem connectivity to help shape the next era of surgery.

"The Stealth AXiS™ surgical system represents the next era of navigation for ENT surgery," said Sean Haag, President of the Ear, Nose, & Throat business at Medtronic. "Building on 25 years of navigation leadership, this system is designed to help surgeons move with greater clarity, confidence, and control in the OR, while creating a powerful platform for the next generation of ENT innovation."

For more information about the Stealth AXiS™ surgical system and the AiBLE™ smart ecosystem, visit www.medtronic.com/stealthaxis.

About the Cranial & Spinal Technologies Business at Medtronic
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery.

About the Ear, Nose, & Throat Business at Medtronic
Medtronic's Ear, Nose, and Throat (ENT) business is the global market leader in ENT, delivering innovative technologies that impact nearly 3 million patients each year. For more than 25 years, we have partnered with physicians to advance care across the specialty. Our portfolio supports surgical procedures related to chronic rhinosinusitis and head and neck cancers, spanning surgical navigation, tissue health, powered instruments, localized drug delivery, intraoperative nerve monitoring, and parathyroid detection. As the global leader in ENT navigation since the introduction of the LandmarX™ image-guided surgery system in 1998, we continue to advance the field with next-generation platforms including the Stealth AXiS™ Surgical System.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Christine Stewart
Public Relations
+1-269-377-2557

Ingrid Goldberg
Investor Relations
+1-763-505-2696

¹Li Z, et al. World Neurosurgery. 2018;116:e291-e297.

 ² Guberman GI, et al. Neurology. 2025;105(9).

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-receives-fda-clearance-for-stealth-axis-surgical-system-for-cranial-and-ent-procedures-302727270.html

SOURCE Medtronic plc

FAQ

What does the FDA clearance for Medtronic's Stealth AXiS (MDT) on March 27, 2026 mean for surgeons?

It permits clinical use of Stealth AXiS for cranial and ENT procedures in the U.S. According to Medtronic, the system unifies navigation, robotics and AI-enabled planning to support precision and real-time insights in the OR.

How does Stealth AXiS (MDT) support cranial surgery with AI-enabled tractography?

It provides AI-based automatic tractography to generate patient-specific brain maps. According to Medtronic, this visualization helps surgeons identify critical neural pathways during pre-op planning and intraoperative decision-making.

What ENT capabilities does Medtronic's Stealth AXiS (MDT) offer after the March 27, 2026 clearance?

Stealth AXiS delivers high-precision navigation and enhanced visualization tailored to sinuses and skull base. According to Medtronic, it offers surgeon-centered workflows, sharper anatomical detail, and faster responsiveness in endoscopic ENT procedures.

Was the Stealth AXiS system previously cleared for other specialties before March 27, 2026?

Yes, it received clearance for spine procedures in February 2026. According to Medtronic, the platform is now cleared across spine, cranial, and ENT specialties to enable multi-specialty use.

How does Stealth AXiS (MDT) integrate intraoperative imaging and ecosystem connectivity?

The system integrates intraoperative ultrasound via GE HealthCare bkActiv for additional real-time imaging. According to Medtronic, its AiBLE ecosystem supports continuous software innovation and deeper device connectivity.